The therapeutic efficacy of antibody-drug conjugates (ADCs) is dependent on the linker-payload system. High-potency cytotoxic payloads present complex molecular structures, synthetic difficulties, and strict impurity limits, which affect project progression from proof-of-concept to IND/IMPD filings, clinical sample preparation, and commercial supply.

Leveraging three proprietary platforms—Phytopower^® Development Platform of Bioactive Molecules & Ingredients from Global Medicinal Plants, Aktinsyn^® Technology Platform of Synthetic Chemistry, and Aktinbio^® Development Platform of Biotechnology, AKTINPHARM® provides CRDMO services for ADC linker-payloads to pharmaceutical enterprises, biotechnology companies, and Marketing Authorization Holders (MAHs).

AKTINPHARM® focuses on the R&D and manufacturing of highly potent small molecules, natural scaffolds, cytotoxic payloads, and linker-ready intermediates. We support critical milestones ranging from payload screening, structural modification, and impurity profiling to purification scale-up and quality specification establishment. Our technical experience in complex high-potency chemistry is applied to transition challenging payload molecules into reproducible and scalable manufacturing processes.

Our services cover the project lifecycle, from early-stage preparation of R&D samples for candidate molecule screening, through systematic optimization and stepwise scale-up of process parameters, to the supply of clinical and commercial batches under cGMP compliance. Throughout this process, rapid early-stage R&D, robust process development, in-depth quality studies, and seamless regulatory compliance are advanced systematically to support the translation of ADC projects. Learn More >> [ https://www.aktin.com/en/contact ]

AKTINPHARM^® Featured Payload Products 

With expertise in complex chemical synthesis and natural scaffold modification, we have established a payload pipeline featuring classic cytotoxic payloads and novel differentiated molecules. Core products include:

α‑Amanitin | CAS: 23109‑05‑9
Triptolide | CAS: 38748‑32‑2 
Calicheamicin | CAS: 108212‑75‑5
Eribulin | CAS: 253128‑41‑5 
SG3199 | CAS: 1595275‑71‑0
Thailanstatin A | CAS: 1426953‑21‑0 
Samrotecan | CAS: 2495742‑34‑0

Additionally, our core compound library contains over 2,000 high-performance core scaffolds, expanding by dozens of entries monthly, providing a molecular database for ADC payload screening and structural optimization.

Production Capacity & Lifecycle Support: From R&D to Commercialization

• R&D Centers: Dedicated to the isolation and purification of botanical active ingredients, QA/QC management, API & formulation CRO services, and the construction of active compound libraries.
• Non-GMP Facility: Focused on early-stage process exploration, route optimization, and non-GMP industrial-scale manufacturing.
• GMP Facility: Powered by a comprehensive QC/QA quality management system to achieve commercial manufacturing of APIs and advanced intermediates, alongside full CRDMO services for innovative drugs.

AKTINPHARM^® integrates discovery, process development, analytics, formulation development, regulatory support, and manufacturing into a unified technological pipeline for synchronized advancement. Through flexible FTE and FFS collaboration models, we support full-scale development needs ranging from non-GMP R&D samples to GMP clinical and commercial supply, as well as from lab-scale and pilot-scale up to commercial manufacturing, catering to our clients' differentiated demands for speed, cost and regulatory compliance at varying stages.

Advance your antibody–drug conjugate program with AKTINPHARM^®.
Complex chemistry. Reliable scale-up. Consistent ADC payload supply.
Contact the AKTINPHARM^® CRDMO team to discuss your ADC linker-payloads project.

Welcome to meet us: CPHI Milan 2026 from Oct. 6-8, Booth No.: 4H109